99 filings
Page 2 of 5
8-K
b0y1r1
20 Jun 23
Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program
6:10am
8-K
6semhw
14 Jun 23
Submission of Matters to a Vote of Security Holders
4:15pm
UPLOAD
atepa cdgtdunlm84h
2 Jun 23
Letter from SEC
12:00am
CORRESP
t5ml05aj t20id
23 May 23
Correspondence with SEC
12:00am
UPLOAD
4bbeyy2pklyr
16 May 23
Letter from SEC
12:00am
8-K
0lmc 862c
8 May 23
Entry into a Material Definitive Agreement
5:21pm
S-3ASR
ei74u97vd1lncj n1
8 May 23
Automatic shelf registration
5:02pm
8-K
eu9c6trfsc
8 May 23
Arcellx Provides First Quarter Financial Results
4:02pm
ARS
y89mt2hf20pao7df
28 Apr 23
Annual report to shareholders
4:12pm
DEFA14A
41uoqyhcpffwdgf9ni
28 Apr 23
Additional proxy soliciting materials
4:07pm
DEF 14A
xmmf5 qk4gu71vsujb4
28 Apr 23
Definitive proxy
4:04pm
PRE 14A
8mf9gw7u4ucx4q2
14 Apr 23
Preliminary proxy
4:52pm
8-K
qako95 3iqv22
29 Mar 23
Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
4:11pm
D
cy6ak6ja0 lh
6 Feb 23
$100.00 mm in equity, sold $100.00 mm, 1 investor
12:42pm
8-K
ri2fvsmhkv9snaz 0h
30 Jan 23
KITE AND ARCELLX CLOSE AGREEMENT TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-ddBCMA IN MULTIPLE MYELOMA
9:18am
S-8
yggh53 mdu7y5y0ptc3
3 Jan 23
Registration of securities for employees
5:12pm
8-K
z44jj
16 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:10pm